Clinical Trial Update: Rivaroxaban for Slow Coronary Flow After PCI in STEMI [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating rivaroxaban for slow coronary flow after percutaneous coronary intervention in ST Elevation Myocardial Infarction and is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• St-elevation Myocardial Infarction

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: ST Elevation Myocardial Infarction, No-Reflow Phenomenon | Phase 4 | Status: NOT_YET_RECRUITING